140608-64-6
Chemical Structure
Muromonab
Synonym(s): Muromanab-CD3
- CAS No.: 140608-64-6
- Formula:N/A
- Molecular Weight:(146.34 kDa)
IUPAC Name: methyl (5S,8S,10aS)-5-((tert-butoxycarbonyl)amino)-3-(2,2-difluoroethyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxylate
SMILES: [Muromonab]
Biological Activity: Muromonab (Muromonab-CD3; OKT3) is a mouse monoclonal antibody targeting the CD3 antigen. Muromonab specifically binds to the CD3 antigen on the surface of human and higher primate T cells. Muromonab blocks the function of T cell receptors to recognize foreign antigens and inhibits T cell-mediated immune responses, including cell-mediated lymphocyte lysis and T cell proliferation responses. Muromonab can be used to study acute kidney, liver, heart and combined kidney-pancreas transplant rejection, and can also be used to study graft-versus-host disease in bone marrow transplant patients[1][2][3][4][5].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Muromonab | 98.74% | Muromonab (Muromonab-CD3; OKT3) is a mouse monoclonal antibody targeting the CD3 antigen. Muromonab specifically binds to the CD3 antigen on the surface of human and higher primate T cells. Muromonab blocks the function of T cell receptors to recognize foreign antigens and inhibits T cell-mediated immune responses, including cell-mediated lymphocyte lysis and T cell proliferation responses. Muromonab can be used to study acute kidney, liver, heart and combined kidney-pancreas transplant rejection, and can also be used to study graft-versus-host disease in bone marrow transplant patients. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. P A Todd, et al. Muromonab CD3. A review of its pharmacology and therapeutic potential. Drugs. 1989 Jun;37(6):871-99. [Content Brief]
- [2]. Lahdou I, et al. Role of human corneal endothelial cells in T-cell-mediated alloimmune attack in vitro. Invest Ophthalmol Vis Sci. 2014 Mar 3;55(3):1213-21. [Content Brief]
- [3]. Yan H, et al. Bone marrow-liver-thymus (BLT) immune humanized mice as a model to predict cytokine release syndrome. Transl Res. 2019 Aug;210:43-56. [Content Brief]
- [4]. Ménoret S, et al. Efficient generation of human immune system rats using human CD34+ cells. Stem Cell Reports. 2024 Sep 10;19(9):1255-1263. [Content Brief]
- [5]. OKT 3. Sciencedirect.
